DelveInsight’s “Primary Hyperoxaluria Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Primary Hyperoxaluria pipeline landscapes.
The report comprises Primary Hyperoxaluria pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Primary Hyperoxaluria therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Primary Hyperoxaluria pipeline products.
Some of the key takeaways from the Primary Hyperoxaluria Pipeline Report:
-
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Biocodex, OxThera, Dicerna Pharmaceuticals, etc., are developing therapies for the treatment of Primary Hyperoxaluria.
-
Emerging therapies such as Stiripentol, Oxabact OC5 – Oxalobacter formigenes HC-1, DCR-PHXC, are expected to have a significant impact on the Primary Hyperoxaluria market in the coming years.
Get an overview of pipeline landscape @ Primary Hyperoxaluria Clinical Trials Analysis
Primary hyperoxaluria (PH) is a family of ultra-rare, life-threatening genetic disorders that cause complications in the kidneys. There are three known genetic types of PH, each resulting from a mutation in one of three different genes. These genetic mutations cause enzyme deficiencies that manifest in the overproduction of a substrate called oxalate. Abnormal production and accumulation of oxalate lead to recurrent kidney stones, nephrocalcinosis, and chronic kidney disease that may progress to an end-stage renal disease requiring regular dialysis and a dual liver-kidney transplant.
Primary Hyperoxaluria Pipeline Therapies along with Key Players:
-
Stiripentol by Biocodex
-
Oxabact OC5 – Oxalobacter formigenes HC-1 by OxThera
-
DCR-PHXC by Dicerna Pharmaceuticals
-
And others.
Scope of Primary Hyperoxaluria Pipeline Drug Insight
-
Coverage: Global
-
Major Players: Biocodex, OxThera, Dicerna Pharmaceuticals, and others.
-
Pipeline Therapies: Stiripentol, Oxabact OC5 – Oxalobacter formigenes HC-1, DCR-PHXC, and others.
Table of Contents
|
1 |
Primary Hyperoxaluria Report Introduction |
|
2 |
Primary Hyperoxaluria Executive Summary |
|
3 |
Primary Hyperoxaluria Overview |
|
4 |
Primary Hyperoxaluria- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Primary Hyperoxaluria Pipeline Therapeutics |
|
6 |
Primary Hyperoxaluria Late Stage Products (Phase II/III) |
|
7 |
Primary Hyperoxaluria Mid Stage Products (Phase II) |
|
8 |
Primary Hyperoxaluria Early Stage Products (Phase I) |
|
9 |
Primary Hyperoxaluria Preclinical Stage Products |
|
10 |
Primary Hyperoxaluria Therapeutics Assessment |
|
11 |
Primary Hyperoxaluria Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Primary Hyperoxaluria Key Companies |
|
14 |
Primary Hyperoxaluria Key Products |
|
15 |
Primary Hyperoxaluria Unmet Needs |
|
16 |
Primary Hyperoxaluria Market Drivers and Barriers |
|
17 |
Primary Hyperoxaluria Future Perspectives and Conclusion |
|
18 |
Primary Hyperoxaluria Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
Get a customized pipeline report @ Primary Hyperoxaluria Drugs Pipeline Report
Related Reports:
DelveInsight’s ‘Primary Hyperoxaluria-Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Primary Hyperoxaluria Epidemiology
DelveInsight’s ‘Primary Hyperoxaluria Epidemiology Forecast to 2030′ report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/